Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

/PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute...

Related Keywords

United States ,Canada ,Americans ,American ,Canadian ,Mahmood Kazemi ,Linkedin ,American Diabetes Association Statistics About Accessed ,Facebook ,American Diabetes Association ,National Diabetes Statistics ,Scientific Sessions ,Freestyle Libre ,American Diabetes ,Style Libre ,Glucose Pattern Insights ,Important Safety ,New Orleans ,Diabetes Treatment ,Diabetes Association ,About Diabetes ,Fast Facts ,National Diabetes Statistics Report ,Accessed May ,Abbott ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Retail ,Pharmaceuticals ,Household ,Onsumer Amp Cosmetics ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,